GlassScriptPhysician profile
John Mc Kernan
NPI 1336197755
$41,390.70
in general payments reported to CMS, 2019-2025
10 companies · $45.03 in 2025
The $45.03 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,524 · 2020: $7,840 · 2021: $5,337 · 2022: $6,975 · 2023: $8,893 · 2024: $4,775 · 2025: $45.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $13K · Food and Beverage: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $13,451.78 |
| Food and Beverage | $261.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $23,163.66 | 2019-2023 | V. Mueller |
| Davol INC. | $10,792.61 | 2021-2023 | V. Mueller |
| Steris Corporation | $6,784.11 | 2023-2024 | |
| Abbvie INC. | $261.94 | 2023-2025 | |
| Allergan, INC. | $164.74 | 2021 | |
| Merz North America, INC. | $97.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.44 | 2019 | |
| Galderma Laboratories, L.P. | $28.81 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.43 | 2019 | |
| Merck Sharp & Dohme LLC | $15.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mc Kernan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.